The article reports on the pursuit of Genentech to develop treatment of the age-related retinal degeneration disorder in the U.S. The company has created Lucentis that is capable of treating common eye diseases and believed to dominate in the market. The antibody therapy has been approved by the Food and Drug Administration after phases of clinical trials.